drugset
Drugs / KT-301
last change Mar 2026 re-read 3 minutes ago

KT-301

also known as US-APR2020

Other / unclassified

Developed for
chronic kidney disease
Investigated by
Kibow Pharma

Trials 1

today NCT05407389 · Ph 2/3
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT05407389 Apr 2022 → Dec 2025 chronic kidney disease Kibow Pharma Suspended No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2022-05-17 Kibow Pharma Kibow Pharmaceuticals Announces Completion of First Patient in Phase II, 6 Months RCT of US-APR2020 and Enrollment in Subsequent 6 Months Open-Label Trial, a Unique Design of a Best-in-Class Add-on Treatment for Chronic Kindy Disease Patients kibowbiotech.com ↗
2021-04-13 Kibow Pharma Kibow Biotech Announces FDA Approval of IND to Initiate Phase II Clinical Trial of US-APR2020 to Treat Chronic Kidney Disease Stage IV kibowbiotech.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as KT-301 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05407389 ↗
Known as US-APR2020 “KT-301 (formerly US-APR2020)” NCT05407389 ↗
Action Restore “intended to restore the gut bacteria balance” NCT05407389 ↗
Modality Other / unclassified “KT-301 (formerly US-APR2020) is a probiotic formulation of bacteria intended to restore the gut bacteria balance” NCT05407389 ↗
Route Oral “will be administered orally” NCT05407389 ↗